Erythropoiesis-Stimulating Agent Treatment in Patients With COVID-19

Am J Kidney Dis. 2020 Sep;76(3):303-305. doi: 10.1053/j.ajkd.2020.05.002. Epub 2020 May 29.

Authors

Steven Fishbane¹, Jamie S Hirsch²

Affiliations

¹ Division of Kidney Diseases and Hypertension, Department of Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell Health, Great Neck, NY. Electronic address: sfishbane@northwell.edu.
² Division of Kidney Diseases and Hypertension, Department of Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell Health, Great Neck, NY.

No abstract available

Publication types

Editorial

MeSH terms

Acute Kidney Injury / blood
Acute Kidney Injury / drug therapy
Acute Kidney Injury / epidemiology
Anemia / blood
Anemia / drug therapy
Anemia / epidemiology
Betacoronavirus*
COVID-19
Coronavirus Infections / blood
Coronavirus Infections / drug therapy*
Coronavirus Infections / epidemiology
Erythropoiesis / drug effects*
Erythropoiesis / physiology
Erythropoietin / blood
Hematinics / pharmacology
Hematinics / therapeutic use*
Humans
Pandemics
Pneumonia, Viral / blood
Pneumonia, Viral / drug therapy*
Pneumonia, Viral / epidemiology
SARS-CoV-2
Treatment Outcome

Substances

Hematinics
Erythropoietin